Discontinued — last reported Q4 '20
Vertex Pharmaceuticals Finance Lease Principal Paid remained flat by 0.0% to $1.35M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 83.9%, from $8.40M to $1.35M. Over 2 years (FY 2023 to FY 2025), Finance Lease Principal Paid shows a downward trend with a -65.3% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase indicates active deleveraging of lease-related debt, while a decrease may signal new lease acquisitions or slower repayment.
This represents the cash outflow used to reduce the principal balance of finance lease liabilities. It indicates the rat...
Commonly reported in the financing section of the cash flow statement for companies with significant leased assets.
is_cvx_finance_lease_principal_paid| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $44.90M | $33.60M | $5.40M |
| YoY Change | — | -25.2% | -83.9% |
We use cookies for analytics. See our Privacy and Cookie Policy.